Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)

This is an open-label, dose escalation and expansion, multi-center phase 2 study evaluating the safety and efficacy of SR-8541A administered orally in combination with intravenous botensilimab and balstilimab in subjects with MSS-CRC with and without active liver metastases.

Trial Details

NCT ID
NCT06589440
Phase
PHASE2
Sponsor
Stingray Therapeutics
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • SR-8541A
Locations (sample)
  • Morristown, New Jersey, United States|40.79677,-74.48154
  • Austin, Texas, United States|30.26715,-97.74306
  • Dallas, Texas, United States|32.78306,-96.80667
  • Houston, Texas, United States|29.76328,-95.36327
  • Tyler, Texas, United States|32.35126,-95.30106

Key Eligibility Criteria

  • Written informed consent from subject
  • Age ≥ 18 years old on the date of consent
  • Histologically confirmed diagnosis of unresectable and metastatic adenocarcinoma of the colon or rectum
  • Non-microsatellite instability high or non-deficient mismatch repair (non-MSI-H/non-dMMR) tumor status per a standard local testing method

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →